Ticker

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate   Kelowna, British Columbia – September 1 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office.  The funds were deposited into the bank…

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated Findings support Lexaria's expanding strategic partnering outreach activities by evidencing…

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here's what investors need to know.

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is…

Kelowna, British Columbia – TheNewswire - August 13, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement (“ MTA ”) with Pegbio Co., Ltd (“ PegBio ”) to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry.…